Evidence map›Paper›PMID 27880009›Full record

Observational studyClinical cardiology2016

Antianginal Efficacy of Ivabradine/Metoprolol Combination in Patients With Stable Angina.

John Zarifis, Manolis Kallistratos, Apostolos Katsivas, investigators of the Prospective, Non-interventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease

Open access · bronzeAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Observational
  5. Article
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

John ZarifisCardiology Department, George Papanikolaou General Hospital, Thessaloniki, Greece.
Manolis KallistratosCardiology Department, Asklepeion General Hospital, Athens, Greece.
Apostolos KatsivasFirst Cardiology Department, Korgialeneio-Benakeio E.E.S. General Hospital, Athens, Greece.
investigators of the Prospective, Non-interventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease
General Hospital Asklepieio Voulas · GRG. Papanikolaou General Hospital · GRHellenic Red Cross · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medical treatment is the main clinical strategy for controlling patients with chronic stable angina and improving their quality of life (QoL). Ivabradine treatment on top of metoprolol decreases angina symptoms and improves QoL in patients with stable angina and coronary artery disease (CAD). This is a post hoc analysis (636 CAD patients given ivabradine/metoprolol free combination) of a prospective, noninterventional study that included 2403 patients with CAD and stable angina. Data were recorded at baseline at 1 and 4 months after inclusion. Patient QoL was assessed using the EQ-5D questionnaire. From baseline to study completion; ivabradine administration on top of metoprolol decreased heart rate (HR) from 80.8 ± 9.6 to 64.2 ± 6.2 bpm (P < 0.001). Mean number of angina attacks decreased from 2.0 ± 2.0/wk to 0.2 ± 0.6/wk (P < 0.001), whereas nitroglycerin consumption decreased from 1.4 ± 1.9 times/wk to 0.1 ± 0.4 times/wk (P < 0.001). The percentage of patients in Canadian Cardiovascular Society angina class III to IV decreased from 15.4% to 1.9% (P < 0.001). The improvement of symptoms and angina class led to a significant 14.7-point increase in EQ-5D questionnaire score (P < 0.001). Patients with increased HR showed greater improvement (P = 0.001). Adherence to treatment during the entire trial was high (98%). Ivabradine combined with metoprolol significantly decreased angina symptoms and use of nitroglycerin in patients with stable angina and CAD, leading to improved QoL. The benefits observed with this combination explain the high rate of adherence to treatment.

Indexed as

Angina, StableBenzazepinesMetoprololAdrenergic beta-1 Receptor AntagonistsAgedCardiovascular AgentsCyclic Nucleotide-Gated Cation ChannelsDose-Response Relationship, DrugDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHumansIvabradineMaleProspective StudiesAdrenergic beta-1 Receptor AntagonistsBenzazepinesCardiovascular AgentsCyclic Nucleotide-Gated Cation ChannelsIvabradineMetoprololivabradinemetoprololnitroglycerin consumptionquality of lifeStable angina

Identifiers

PMID27880009
PMCPMC6490866
OpenAlexW2558169777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.